Telix Pharmaceuticals Ltd.
Industry Group: Pharmaceuticals
Country/Region: Australia
Identifier: ASX:TLX
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney), and glioblastoma (brain) cancer. Geographically, It operates through two reportable segments Commercial operations which include Commercial sales of Illuccix® and other products after obtaining regulatory approvals and Product development includes Developing radiopharmaceutical products for commercialisation. This segment includes revenue received from license agreements before commercialization and research and development services. It operates in Australia, the United States, Belgium, and Japan.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 435 out of 922
Universe
Global Universe 10332 out of 16179
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
SK bioscience Co., Ltd. |
23.9
Medium
|
167 out of 922 |
Walvax Biotechnology Co., Ltd. |
27.6
Medium
|
388 out of 922 |
Xenon Pharmaceuticals, Inc. |
27.7
Medium
|
400 out of 922 |
Telix Pharmaceuticals Ltd. |
28.2
Medium
|
435 out of 922 |
Shenzhen Kangtai Biological Products Co., Ltd. |
30.4
High
|
549 out of 922 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Telix Pharmaceuticals Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Telix Pharmaceuticals Ltd.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Top Material ESG Issues for Telix Pharmaceuticals Ltd.
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted Telix Pharmaceuticals Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level